Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
@neilin
Thank you as always for responding to my request for your thoughts. I’m glad you did.
Your knowledge is invaluable to people like me that don’t normally invest in biotech.
I took your advice and read that paper this morning. Whilst a good proportion of it went over my head, it did outline the processes that you mentioned; optimisation, validation and standardisation. It also outlined the huge amount of work involved within each of these 3 stages in order to bring a watertight product to market.
I know realise that I need to throttle back on my uninformed timeframes. At least I’m now more aware of what’s actually going on behind the scenes so I can reset my expectations.
I see where you got the veterinary angle from. Lol.
Thanks again.
VV
78p?
Are great as an aid to the overall picture but trading purely on technicals won’t take into account such things as macro events, like sentiment, RNSs, wider market sell-offs, inflation, oil price (in this case) yada, yada.
Technical trading play their part, but they can’t always predict the direction because of the sheer amount of background noise.
This was posted by auson1 on ADVFN yesterday-
stock on loan here was 13.13% at end of April up from 12.25% at end March.
A very well articulated and balanced post LB.
I would welcome Neilin’s input on the time it is taking to move the test to the next stage.
Tia.
Euroclear
alternatively, it could be shorter’s continuing to reduce their positions.
Sm66, there isn’t a list for shorts under 0.5%.
0.5% is the 1st threshold on which short positions must be declared.
I’ve come across some proper cranks in my time on these boards but that nimrod esecallum is right up there.
Waste of oxygen, filtered.
Thanks fishslicer, I thought your original post was an update from yesterdays date.
Yes, thank you.
That’s the data I’ve seen.
I’d be interested to know where you saw that, as the data I’ve looked at shows no change since the day before results were reported.
Tia.
They can now buy shares and it would only add to the confidence if they did.
I’d assume HSBC are one of them.
@Pokerchips
I’d be interested to know who our lenders actually are.
Genuine q.
“ I suppose the only certain way to stop shorters selling you shares is to hold them as certificates, which is not really practical.”
Or you could put a sell order on your shares for say…£5 per share.
That way your nominee company can’t lend out your shares.
“ Does ADNOC hold a grudge against firms that are very active across the green infrastructure landscape?”
Nope! They look for best in class at delivering projects.
Best to ignore the occasional visit by somebody that hasn’t a clue what they’re talking about.
The value will eventually out here.
C/o OAPKnob1 on ADVFN…
MURF need to get their finger out their farter and complete the Conduit Pharmaceuticals Limited merger.
On April 10, 2023, Murphy Canyon Acquisition Corp. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that, for the previous 30 consecutive business days, the Market Value of Listed Securities (“MVLS”) for the Class A Common Stock of the Company, par value $0.0001 per share (“Class A Common Stock”), was below the $50 million minimum MVLS requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Rule”). The Letter is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities.
In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company will have 180 calendar days, or until October 9, 2023 (the “Compliance Date”), to regain compliance with the MVLS Rule. To regain compliance with the MVLS Rule, the MVLS for the Class A Common Stock must be at least $50 million for a minimum of 10 consecutive business days at any time during this 180-day period. If the Company regains compliance with the MVLS Rule, Nasdaq will provide the Company with written confirmation and will close the matter.
If the Company does not regain compliance with the MVLS Rule by the Compliance Date, Nasdaq will provide notice that the Class A Common Stock will be subject to delisting. In the event of such notification, the Nasdaq rules permit the Company an opportunity to appeal Nasdaq’s determination. The Letter notes that the Company may be eligible to transfer the listing of its securities to the Nasdaq Capital Market (provided that it then satisfies the requirements for continued listing on that market). The Company is monitoring the MVLS of its Class A Common Stock and will consider options available to it to potentially achieve compliance.
https://www.youtube.com/live/PX2qoy9ViIg?feature=share
Nothing particularly new, but being talked about.
19mins in.